Koura Zephex®

World leaders in the manufacture and supply of very high purity HFA medical propellants. Zephex® propellants are used in around 75% of the world’s MDIs

[Koura Zephex® @Zephex_Pharma]

We would like to inform our followers that this page dedicated to Koura Zephex® has transitioned to Koura.

Please consider following @Koura_Global to stay up to date on Zephex® products and developments.

#WeAreOrbia

[Koura Zephex® @Zephex_Pharma]

We would like to inform our followers that this page dedicated to Koura Zephex® is transitioning to Koura.

Please consider following @Koura_Global to stay up to date on Zephex® products and developments.

[Koura Zephex® @Zephex_Pharma]

As a chronic disease with no cure, asthma requires lifelong management, most frequently through inhalers. Read about why Koura Zephex® has developed a new medical propellant for inhalers that is both environmentally and user-friendly: https://t.co/Yby4vdX13E

[Koura Zephex® @Zephex_Pharma]

Koura Zephex® provides innovative medical propellants to the world’s biggest pharmaceutical companies. All of our products are produced to the most demanding industry standards at our dedicated facilities to ensure high performance and sustainability: https://t.co/zSkSMak71B

[Koura Zephex® @Zephex_Pharma]

Innovation is key to ensuring that essential medical products are delivered to patients in a sustainable way. Zephex® 152a, our new medical propellant for metered dose inhalers, is an important step in the industry's journey towards low GWP solutions: https://t.co/wmELQDPxub

[Koura Zephex® @Zephex_Pharma]

To support the development of Zephex® 152a, our sustainable medical propellant, we’re working with medical and environmental regulators to ensure that our customers’ new inhaler products are in line with the changing regulatory landscape: https://t.co/qWlDjGPhGe"

[Koura Zephex® @Zephex_Pharma]

At the recent @rddonline conference in Orlando Florida, Koura and our industry partners hosted a number of presentations featuring 152a, our innovative and sustainable new medical propellant. Find out more and access the presentations here: https://t.co/ernpFIcKKJ

[Koura Zephex® @Zephex_Pharma]

'Our Route to Net Zero', a series of films by @See_Chem_Bus and @ITNPIndNews, shows how Koura and other companies are at the forefront of developing sustainable industry solutions – vital in helping the UK achieve its net zero target by 2050: https://t.co/aUl2wTQ87s

[Koura Zephex® @Zephex_Pharma]

We were delighted that Alessandro Chiesi, CCO at pharmaceuticals group Chiesi, was able to join us at the recent opening of a new production facility for Zephex® 152a. Chiesi is bringing the new sustainable medical propellant to its product development: https://t.co/LBS2ETbIuk

[Koura Zephex® @Zephex_Pharma]

“The impact of transitioning pMDIs to Zephex® 152a has significant potential for the NHS’s environmental aspirations.” Read about why our new medical propellant is a game-changer for sustainability in healthcare: https://t.co/GjAMsp37Yn

[Koura Zephex® @Zephex_Pharma]

We’re excited to have recently opened a new production facility for HFA 152a, our sustainable medical propellant for use in pressurised metered dose inhalers (pMDIs). The new propellant will reduce the carbon footprint of pMDI inhalers by up to 90%. https://t.co/LBS2ETbIuk

[Koura Zephex® @Zephex_Pharma]

Koura’s Simon Gardner recently provided an update on Zephex® 152a, our sustainable medical propellant for use in inhalers. From our new manufacturing facility in Cheshire, to the R&D process behind the product, you can read Simon’s insights here: https://t.co/5GrLyMxz5I

[Koura Zephex® @Zephex_Pharma]

Koura is supporting pharmaceutical partners who are currently seeking to transition their existing inhaler products to our new sustainable medical propellant, Zephex® 152a. Through our UK formulation facilities, we’re making a range of services available: https://t.co/Ul6JcpR314

[Koura Zephex® @Zephex_Pharma]

Zephex® 152a delivers a greater than 90% reduction in global warming potential compared to some current medical propellants. Learn about the long journey the industry has been on in its transition from environmentally damaging CFCs to Zephex® 152a: https://t.co/Hpdrxjc20h

[Koura Zephex® @Zephex_Pharma]

Read our article on how Koura is meeting its mission to “advance life around the world” by developing a new sustainable solution for inhalers with Zephex® 152a: https://t.co/GjAMsp37Yn

[Koura Zephex® @Zephex_Pharma]

We’re thrilled to announce the opening of our new production facility for Zephex® 152a. A significant milestone in delivering the environmentally-friendly medical propellant which has a low GWP and will see commercial-scale Zephex 152a availability in the market by mid-2022.

[Koura Zephex® @Zephex_Pharma]

Our Zephex® team has worked tirelessly to produce record levels of our Zephex 134a medical propellant during the pandemic, ensuring the continued supply of a fundamental product in the treatment of respiratory conditions. Learn more about Zephex® here: https://t.co/89kx20L7br

[Koura Zephex® @Zephex_Pharma]

With asthma affecting an estimated 330 million people globally, our sustainable medical propellant Zephex® 152a is a game-changer for inhaled drug delivery as it significantly reduces the environmental impact of an everyday and widely used medical device: https://t.co/j23PDbiSXe

[Koura Zephex® @Zephex_Pharma]

Koura’s Simon Gardner explains how our Zephex® team has channelled R&D investment into creating a new, sustainable medical propellant that offers a greater than 90% reduction in global warming potential: https://t.co/5GrLyMxz5I

[Koura Zephex® @Zephex_Pharma]

The opening of our new commercial manufacturing facility for Zephex® 152a is a significant milestone for inhaled drug development. The site in Runcorn is able to make several hundred tonnes of this low global warming potential propellant per year: https://t.co/GjAMsp37Yn